| 王 浩,韩 尚,纪雅玲,张 瑶,汪海岩.信迪利单抗注射液联合XELOX方案对晚期胃癌患者PD-1、PD-L1表达和外周血髓源性抑制细胞、调节性T细胞的影响[J].现代生物医学进展英文版,2024,(14):2790-2793. |
| 信迪利单抗注射液联合XELOX方案对晚期胃癌患者PD-1、PD-L1表达和外周血髓源性抑制细胞、调节性T细胞的影响 |
| Effect of Xindili Monoclonal Antibody Injection Combined with XELOX Regimen on PD-1, PD-L1 Expression and Peripheral Blood Myeloid-Derived Suppressor Cells and Regulatory T Cells in Patients with Advanced Gastric Cancer |
| Received:February 27, 2024 Revised:March 23, 2024 |
| DOI：10.13241/j.cnki.pmb.2024.14.037 |
| 中文关键词: 信迪利单抗注射液 XELOX方案 晚期胃癌 PD-1 PD-L1 髓源性抑制细胞 调节性T细胞 |
| 英文关键词: Xindili monoclonal antibody injection XELOX regimen Advanced gastric cancer PD-1 PD-L1 Myeloid-derived suppressor cells Regulatory T cells |
| 基金项目:江苏省卫健委高层次卫生人才"六个一工程"拔尖人才科研项目（LGY2020006） |
|
| Hits: 5 |
| Download times: 9 |
| 中文摘要: |
| 摘要 目的：观察信迪利单抗注射液联合奥沙利铂联合卡培他滨（XELOX）方案对晚期胃癌患者程序性死亡受体-1（PD-1）、程序性死亡配体-1（PD-L1）表达和外周血髓源性抑制细胞（MDSCs）、调节性T细胞（Treg）的影响。方法：选择2021年4月~2023年3月期间我院接收的121例晚期胃癌患者。按照随机数字表法将患者分为对照组（n=60, 接受XELOX方案）和观察组（n=61，接受信迪利单抗注射液联合XELOX方案）。对比两组疗效、不良反应发生率、肿瘤标志物、PD-1、PD-L1 mRNA相对表达量、Treg和MDSCs所占外周血单个核细胞（PBMC）比率。结果：与对照组的ORR（25.00%）、DCR（48.33%）相比，观察组的ORR（40.98%）、DCR（73.77%）更高（P<0.05）。观察组治疗后糖类抗原125（CA125）、癌胚抗原（CEA）、鳞状细胞癌抗原（SCC-Ag）、PD-1、PD-L1 mRNA相对表达量、Treg和MDSCs所占PBMC比率均低于对照组（P<0.05）。两组不良反应发生率组间对比未见差异（P>0.05）。结论：信迪利单抗注射液联合XELOX方案治疗晚期胃癌患者，可降低血清肿瘤标志物水平，调节PD-1、PD-L1表达和Treg和MDSCs所占PBMC比率，有效控制疾病进展。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effect of xindili monoclonal antibody injection combined with oxaliplatin and capecitabine (XELOX) regimen on the expression of programmed death receptor-1 (PD-1) and programmed death ligand-1 (PD-L1) and peripheral blood myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Treg) in patients with advanced gastric cancer. Methods: 121 patients with advanced gastric cancer received in our hospital from April 2021 to March 2023 were selected. Patients were divided into control group (n=60, received XELOX regimen) and observation group (n=61, received xindili monoclonal antibody injection combined with XELOX regimen) according to the random number table method. The efficacy, incidence of adverse reactions, tumor markers, relative expression of PD-1 and PD-L1 mRNA, and the ratio of Treg and MDSCs to peripheral blood mononuclear cells (PBMC) were compared between two groups. Results: Compared with the ORR(25.00 %) and DCR (48.33 %) in control group, the ORR (40.98 %) and DCR (73.77 %) in observation group were higher (P<0.05). After treatment, the relative expression of carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC-Ag), PD-1, PD-L1 mRNA, the ratio of Treg and MDSCs to PBMC in observation group were lower than those in control group(P<0.05). There was no difference in the incidence of adverse reactions between two groups (P>0.05). Conclusion: Xindili monoclonal antibody injection combined with XELOX regimen in the treatment of patients with advanced gastric cancer, which can reduce the level of serum tumor markers, regulate the expression of PD-1, PD-L1 and the ratio of Treg and MDSCs to PBMC, and effectively control the progression of the disease. |
|
View Full Text
View/Add Comment Download reader |
| Close |
